Iron Therapy in Erythropoietic Protoporphyria

Oral Iron Therapy in Erythropoietic Protoporphyria

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05572125

Enrollment

Registered

2022-10-07

Start date

2022-10-17

Completion date

2023-02-14

Last updated

2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythropoietic Protoporphyria, Iron-deficiency

Brief summary

Giving oral iron to patients with erythropoietic protoporphyria (EPP) who is iron deficient is thought to be beneficial. This is, however, not well documented. The purpose of this study is to investigate the effect and safety of oral iron in patients with EPP who is taking iron tablets due to iron deficiency.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosed with EPP * Taking standard dose of iron tablets due to iron deficiency

Exclusion criteria

* Pregnant * Lactating

Design outcomes

Primary

Measure	Time frame
Change in erythrocyte protoporphyrin concentration	Before treatment and after 6-8 weeks of treatment

Secondary

Measure	Time frame
Change in hemoglobin and iron parameters	Before treatment and after 6-8 weeks of treatment
Adverse event	6-8 weeks of treatment

Countries

Denmark

Outcome results